The individual was admitted with complaints of sudden action tremor manifestation, severe abnormality of coagulation observed, impaired vibratory sensation observed, diagnosed with sudden aphasia. Laboratory evaluations detected gene variant P765T. Clinical monitoring is ongoing.
The patient presented to the clinic with presence of intermittent stooped posture, clinical signs of mild elevated gamma-glutamyltransferase level, focal motor seizure manifestation, acute gait ataxia. Diagnostic workup revealed gene variant c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu). Treatment was initiated accordingly.
Upon examination, episodic aphasia symptoms were noted. Further imaging and laboratory tests identified gene variant p.Arg627Gln and p.Arg852Cys. The patient was started on a tailored therapeutic plan.
Upon examination, persistent stooped posture observed, severe eeg with parietal epileptiform discharges condition, episodic gait ataxia observed, severe abnormality of coagulation symptoms were noted. Further imaging and laboratory tests identified gene variant c.3102delG (p.Lys1035Serfs*59) and c.3286C>T (p.Arg1096Cys). The patient was started on a tailored therapeutic plan.
Upon examination, abnormality of coagulation detected, severe reduced tendon reflexes detected, acute aphasia manifestation were noted. Further imaging and laboratory tests identified gene variant c.1288A>T and c.2752T>C. The patient was started on a tailored therapeutic plan.
A medical history of presence of acute eeg with parietal epileptiform discharges, moderate reduced tendon reflexes manifestation, gait ataxia observed was documented. Genetic analysis confirmed gene variant c3239G>C p.Ser1080Thr. Supportive care and follow-up were recommended.
A medical history of clinical signs of chronic eeg with parietal epileptiform discharges, chronic elevated gamma-glutamyltransferase level manifestation, progressive focal motor seizure symptoms was documented. Genetic analysis confirmed gene variant A467T. Supportive care and follow-up were recommended.
The patient presented to the clinic with acute aphasia observed, elevated gamma-glutamyltransferase level detected. Diagnostic workup revealed gene variant c.2584G>A p.A862T and c.830A>T p.H277L. Treatment was initiated accordingly.
The individual was admitted with complaints of moderate gait ataxia condition, moderate abnormality of coagulation detected, episodic eeg with parietal epileptiform discharges manifestation. Laboratory evaluations detected gene variant C752T (T251I) and C1760T (P587L). Clinical monitoring is ongoing.
Initial symptoms included clinical signs of severe elevated gamma-glutamyltransferase level. Subsequent investigations showed gene variant A467T and W748S. Management involved both pharmacological and rehabilitative approaches.
A medical history of diagnosed with intermittent aphasia, persistent abnormality of coagulation observed was documented. Genetic analysis confirmed gene variant c.1399G>A p.Ala467Thr and c.3626_3629dupGATA. Supportive care and follow-up were recommended.
The individual was admitted with complaints of sudden reduced tendon reflexes observed. Laboratory evaluations detected gene variant c.3643+1G>A and c.2396C>A (p.S799Y). Clinical monitoring is ongoing.
Upon examination, clinical signs of acute aphasia, diagnosed with acute abnormality of coagulation, episodic eeg with parietal epileptiform discharges, impaired vibratory sensation detected were noted. Further imaging and laboratory tests identified gene variant c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu). The patient was started on a tailored therapeutic plan.
Initial symptoms included intermittent focal motor seizure, presence of intermittent impaired vibratory sensation, presence of moderate action tremor, progressive eeg with parietal epileptiform discharges condition. Subsequent investigations showed gene variant p.Arg627Gln and p.Arg852Cys. Management involved both pharmacological and rehabilitative approaches.
A medical history of chronic focal motor seizure, episodic elevated gamma-glutamyltransferase level observed, clinical signs of action tremor was documented. Genetic analysis confirmed gene variant Tyr955Cys. Supportive care and follow-up were recommended.
The individual was admitted with complaints of persistent abnormality of coagulation observed, sudden elevated gamma-glutamyltransferase level, acute action tremor observed. Laboratory evaluations detected gene variant R853W and G737R. Clinical monitoring is ongoing.
A medical history of clinical signs of mild elevated gamma-glutamyltransferase level was documented. Genetic analysis confirmed gene variant c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu). Supportive care and follow-up were recommended.
The individual was admitted with complaints of severe impaired vibratory sensation detected, history of acute stooped posture, diagnosed with progressive action tremor, history of moderate abnormality of coagulation. Laboratory evaluations detected gene variant c911T > G (p. L304R) and 3240-3242 duplication (pR1081dup). Clinical monitoring is ongoing.
A medical history of episodic stooped posture manifestation, diagnosed with progressive reduced tendon reflexes, clinical signs of mild action tremor was documented. Genetic analysis confirmed gene variant P765T. Supportive care and follow-up were recommended.
Upon examination, reduced tendon reflexes manifestation were noted. Further imaging and laboratory tests identified gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 − 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of history of mild impaired vibratory sensation, diagnosed with progressive focal motor seizure. Laboratory evaluations detected gene variant R853W and G737R. Clinical monitoring is ongoing.
The patient presented to the clinic with acute focal motor seizure, presence of intermittent elevated gamma-glutamyltransferase level. Diagnostic workup revealed gene variant c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu). Treatment was initiated accordingly.
The individual was admitted with complaints of clinical signs of persistent gait ataxia, presence of mild elevated gamma-glutamyltransferase level. Laboratory evaluations detected . Clinical monitoring is ongoing.
The patient presented to the clinic with progressive reduced tendon reflexes, moderate impaired vibratory sensation condition, diagnosed with progressive focal motor seizure. Diagnostic workup revealed . Treatment was initiated accordingly.
A medical history of mild gait ataxia condition, severe reduced tendon reflexes detected, episodic focal motor seizure symptoms, diagnosed with acute stooped posture was documented. Genetic analysis confirmed gene variant c. 2243G>C (p. W748S). Supportive care and follow-up were recommended.
Upon examination, presence of mild eeg with parietal epileptiform discharges, acute action tremor manifestation, chronic impaired vibratory sensation observed, intermittent focal motor seizure were noted. Further imaging and laboratory tests identified gene variant 1868T>G  L623W and 2263A>G K755E. The patient was started on a tailored therapeutic plan.
Upon examination, severe abnormality of coagulation symptoms, history of progressive reduced tendon reflexes, progressive eeg with parietal epileptiform discharges condition, sudden aphasia observed were noted. Further imaging and laboratory tests identified . The patient was started on a tailored therapeutic plan.
A medical history of abnormality of coagulation detected, persistent elevated gamma-glutamyltransferase level manifestation, history of sudden reduced tendon reflexes, presence of episodic impaired vibratory sensation was documented. Genetic analysis confirmed gene variant c.752C>T (p.T251I) and c.2542G>A (p.G848S). Supportive care and follow-up were recommended.
Initial symptoms included clinical signs of mild impaired vibratory sensation. Subsequent investigations showed gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of acute abnormality of coagulation symptoms, clinical signs of mild reduced tendon reflexes, presence of persistent impaired vibratory sensation, severe aphasia manifestation. Laboratory evaluations detected gene variant p.Arg627Gln and p.Arg852Cys. Clinical monitoring is ongoing.
The individual was admitted with complaints of intermittent eeg with parietal epileptiform discharges symptoms, presence of chronic aphasia, intermittent action tremor. Laboratory evaluations detected gene variant A467T and W748S. Clinical monitoring is ongoing.
A medical history of intermittent action tremor, clinical signs of persistent gait ataxia, clinical signs of elevated gamma-glutamyltransferase level was documented. Genetic analysis confirmed gene variant c.2864A>G (p.Tyr955Cys). Supportive care and follow-up were recommended.
Upon examination, history of moderate impaired vibratory sensation, clinical signs of chronic abnormality of coagulation, chronic stooped posture detected, clinical signs of persistent focal motor seizure were noted. Further imaging and laboratory tests identified gene variant c.1156C>T p.R386C and c.2794C>T p.H932Y. The patient was started on a tailored therapeutic plan.
Upon examination, presence of intermittent aphasia, progressive stooped posture symptoms, intermittent impaired vibratory sensation detected were noted. Further imaging and laboratory tests identified gene variant c.2243G>C. The patient was started on a tailored therapeutic plan.
Initial symptoms included mild impaired vibratory sensation manifestation. Subsequent investigations showed gene variant c.2243G>C. Management involved both pharmacological and rehabilitative approaches.
Upon examination, severe stooped posture condition were noted. Further imaging and laboratory tests identified gene variant c.3311C>G (p.S1104C) and c.2542G>A (p.G848S). The patient was started on a tailored therapeutic plan.
Upon examination, persistent focal motor seizure observed, history of moderate reduced tendon reflexes were noted. Further imaging and laboratory tests identified gene variant c.3311C>G (p.S1104C) and c.2542G>A (p.G848S). The patient was started on a tailored therapeutic plan.
Initial symptoms included eeg with parietal epileptiform discharges detected, severe impaired vibratory sensation observed, elevated gamma-glutamyltransferase level. Subsequent investigations showed gene variant c.2864A>G (p.Tyr955Cys). Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with episodic action tremor observed, presence of acute focal motor seizure. Diagnostic workup revealed . Treatment was initiated accordingly.
Upon examination, history of episodic aphasia, impaired vibratory sensation manifestation, diagnosed with progressive gait ataxia were noted. Further imaging and laboratory tests identified gene variant 1399G→A (A467T). The patient was started on a tailored therapeutic plan.
A medical history of persistent eeg with parietal epileptiform discharges observed was documented. Genetic analysis confirmed gene variant W748S and c.3643+2T>C. Supportive care and follow-up were recommended.
The patient presented to the clinic with focal motor seizure manifestation. Diagnostic workup revealed gene variant c.2864A>G (p.Tyr955Cys). Treatment was initiated accordingly.
The individual was admitted with complaints of clinical signs of chronic gait ataxia, presence of chronic stooped posture, episodic action tremor, moderate reduced tendon reflexes observed. Laboratory evaluations detected gene variant c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu). Clinical monitoring is ongoing.
The individual was admitted with complaints of history of sudden impaired vibratory sensation. Laboratory evaluations detected gene variant c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu). Clinical monitoring is ongoing.
The patient presented to the clinic with diagnosed with persistent aphasia, sudden action tremor observed. Diagnostic workup revealed gene variant A467T and W748S. Treatment was initiated accordingly.
The patient presented to the clinic with sudden gait ataxia, diagnosed with acute abnormality of coagulation. Diagnostic workup revealed gene variant A467T and W748S. Treatment was initiated accordingly.
The individual was admitted with complaints of mild elevated gamma-glutamyltransferase level observed. Laboratory evaluations detected gene variant c.1399G>A p.Ala467Thr and c.3626_3629dupGATA. Clinical monitoring is ongoing.
Upon examination, persistent eeg with parietal epileptiform discharges symptoms were noted. Further imaging and laboratory tests identified gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). The patient was started on a tailored therapeutic plan.
Upon examination, gait ataxia manifestation, acute impaired vibratory sensation manifestation were noted. Further imaging and laboratory tests identified gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. The patient was started on a tailored therapeutic plan.
Initial symptoms included progressive aphasia condition. Subsequent investigations showed gene variant c.2864A>G (p.Tyr955Cys). Management involved both pharmacological and rehabilitative approaches.
Upon examination, persistent stooped posture symptoms, acute elevated gamma-glutamyltransferase level detected, sudden impaired vibratory sensation observed, clinical signs of intermittent aphasia were noted. Further imaging and laboratory tests identified gene variant p.Arg953Cys. The patient was started on a tailored therapeutic plan.
A medical history of chronic eeg with parietal epileptiform discharges symptoms, diagnosed with intermittent stooped posture was documented. Genetic analysis confirmed gene variant A467T and W748S. Supportive care and follow-up were recommended.
Upon examination, presence of chronic stooped posture were noted. Further imaging and laboratory tests identified gene variant c.752C>T p.T251I and c.1760C>T p.P587L. The patient was started on a tailored therapeutic plan.
Initial symptoms included diagnosed with aphasia. Subsequent investigations showed gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with severe abnormality of coagulation symptoms, chronic action tremor, chronic eeg with parietal epileptiform discharges detected. Diagnostic workup revealed gene variant c.3286C>T (p.Arg1096Cys). Treatment was initiated accordingly.
The patient presented to the clinic with elevated gamma-glutamyltransferase level symptoms, chronic gait ataxia, presence of progressive impaired vibratory sensation, diagnosed with mild reduced tendon reflexes. Diagnostic workup revealed gene variant c.3311C>G (p.S1104C) and c.2542G>A (p.G848S). Treatment was initiated accordingly.
The patient presented to the clinic with sudden action tremor. Diagnostic workup revealed gene variant c.752C>T (p.T251I) and c.2542G>A (p.G848S). Treatment was initiated accordingly.
Initial symptoms included severe aphasia observed, sudden eeg with parietal epileptiform discharges symptoms, presence of acute impaired vibratory sensation. Subsequent investigations showed gene variant p.A467T and c.2157+5_6GC>AG. Management involved both pharmacological and rehabilitative approaches.
Upon examination, presence of sudden abnormality of coagulation were noted. Further imaging and laboratory tests identified gene variant c.2584G>A p.A862T and c.830A>T p.H277L. The patient was started on a tailored therapeutic plan.
A medical history of elevated gamma-glutamyltransferase level, history of intermittent eeg with parietal epileptiform discharges was documented. Genetic analysis confirmed gene variant c.3286C>T (p.Arg1096Cys). Supportive care and follow-up were recommended.
Upon examination, moderate action tremor condition, clinical signs of severe reduced tendon reflexes were noted. Further imaging and laboratory tests identified gene variant 1399G→A (A467T). The patient was started on a tailored therapeutic plan.
Upon examination, history of progressive aphasia, persistent stooped posture condition, clinical signs of episodic action tremor were noted. Further imaging and laboratory tests identified gene variant p.A467T and c.2157+5_6GC>AG. The patient was started on a tailored therapeutic plan.
Initial symptoms included chronic elevated gamma-glutamyltransferase level detected, persistent reduced tendon reflexes observed, presence of chronic impaired vibratory sensation. Subsequent investigations showed gene variant T251I/P587L and R807C. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of progressive elevated gamma-glutamyltransferase level, progressive eeg with parietal epileptiform discharges, clinical signs of severe stooped posture, history of chronic abnormality of coagulation. Laboratory evaluations detected gene variant A467T and W748S. Clinical monitoring is ongoing.
Initial symptoms included episodic impaired vibratory sensation detected, moderate reduced tendon reflexes observed, episodic action tremor detected, progressive stooped posture observed. Subsequent investigations showed gene variant c.1288A>T and c.2752T>C. Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included diagnosed with chronic gait ataxia, history of acute eeg with parietal epileptiform discharges. Subsequent investigations showed gene variant c.1399G>A p.Ala467Thr and c.2542G>A p.Gly848Ser. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of sudden elevated gamma-glutamyltransferase level condition, action tremor manifestation, history of persistent gait ataxia, episodic stooped posture detected. Laboratory evaluations detected . Clinical monitoring is ongoing.
Upon examination, clinical signs of chronic abnormality of coagulation, mild eeg with parietal epileptiform discharges, presence of acute elevated gamma-glutamyltransferase level were noted. Further imaging and laboratory tests identified gene variant c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu). The patient was started on a tailored therapeutic plan.
Upon examination, intermittent action tremor manifestation, history of progressive reduced tendon reflexes, acute gait ataxia symptoms, episodic aphasia symptoms were noted. Further imaging and laboratory tests identified gene variant c.1399G>A (p.A467T) and c.3285C>G (p.S1095R). The patient was started on a tailored therapeutic plan.
Initial symptoms included diagnosed with severe focal motor seizure, intermittent gait ataxia manifestation. Subsequent investigations showed gene variant R853W and G737R. Management involved both pharmacological and rehabilitative approaches.
A medical history of clinical signs of chronic abnormality of coagulation was documented. Genetic analysis confirmed gene variant A467T and W748S. Supportive care and follow-up were recommended.
Upon examination, persistent abnormality of coagulation detected, chronic aphasia manifestation, acute reduced tendon reflexes, presence of persistent action tremor were noted. Further imaging and laboratory tests identified gene variant c911T > G (p. L304R) and 3240-3242 duplication (pR1081dup). The patient was started on a tailored therapeutic plan.
Upon examination, presence of gait ataxia, progressive stooped posture condition, action tremor, diagnosed with acute eeg with parietal epileptiform discharges were noted. Further imaging and laboratory tests identified gene variant p.Arg953Cys. The patient was started on a tailored therapeutic plan.
A medical history of action tremor condition, clinical signs of impaired vibratory sensation, severe stooped posture detected, intermittent abnormality of coagulation detected was documented. Genetic analysis confirmed gene variant W748S and c.3643+2T>C. Supportive care and follow-up were recommended.
Initial symptoms included impaired vibratory sensation observed, presence of episodic abnormality of coagulation, eeg with parietal epileptiform discharges symptoms, sudden action tremor. Subsequent investigations showed gene variant p.A467T and c.2157+5_6GC>AG. Management involved both pharmacological and rehabilitative approaches.
Upon examination, presence of acute aphasia, clinical signs of sudden elevated gamma-glutamyltransferase level were noted. Further imaging and laboratory tests identified . The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of acute eeg with parietal epileptiform discharges detected, clinical signs of chronic reduced tendon reflexes. Laboratory evaluations detected gene variant 1868T>G  L623W and 2263A>G K755E. Clinical monitoring is ongoing.
Initial symptoms included chronic gait ataxia condition, severe elevated gamma-glutamyltransferase level manifestation, diagnosed with moderate aphasia. Subsequent investigations showed gene variant c.1288A>T p.M430L and c.2752T>C p.W918R. Management involved both pharmacological and rehabilitative approaches.
Upon examination, presence of intermittent elevated gamma-glutamyltransferase level, focal motor seizure symptoms were noted. Further imaging and laboratory tests identified gene variant R853W and G737R. The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of severe stooped posture detected, presence of episodic abnormality of coagulation, acute eeg with parietal epileptiform discharges detected. Laboratory evaluations detected gene variant c. 2243G>C (p. W748S). Clinical monitoring is ongoing.
Initial symptoms included episodic action tremor symptoms. Subsequent investigations showed gene variant c.752C>T (p.T251I) and c.3572A>G (p.K1191R). Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included diagnosed with focal motor seizure, mild eeg with parietal epileptiform discharges condition, episodic aphasia symptoms, presence of acute reduced tendon reflexes. Subsequent investigations showed gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. Management involved both pharmacological and rehabilitative approaches.
Upon examination, progressive gait ataxia symptoms, chronic eeg with parietal epileptiform discharges manifestation, abnormality of coagulation manifestation were noted. Further imaging and laboratory tests identified gene variant c.3311C>G (p.S1104C) and c.2542G>A (p.G848S). The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with severe gait ataxia symptoms, sudden reduced tendon reflexes manifestation, severe impaired vibratory sensation symptoms. Diagnostic workup revealed gene variant A467T and W748S. Treatment was initiated accordingly.
Initial symptoms included chronic impaired vibratory sensation observed, progressive eeg with parietal epileptiform discharges condition, clinical signs of persistent action tremor, presence of chronic elevated gamma-glutamyltransferase level. Subsequent investigations showed gene variant c.1399G>A p.Ala467Thr and c.3626_3629dupGATA. Management involved both pharmacological and rehabilitative approaches.
A medical history of sudden elevated gamma-glutamyltransferase level manifestation, presence of severe action tremor was documented. Genetic analysis confirmed gene variant W748S. Supportive care and follow-up were recommended.
A medical history of moderate abnormality of coagulation symptoms, episodic gait ataxia symptoms, presence of sudden focal motor seizure was documented. Genetic analysis confirmed gene variant c.1288A>T p.M430L and c.2752T>C p.W918R. Supportive care and follow-up were recommended.
Initial symptoms included persistent aphasia manifestation. Subsequent investigations showed gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). Management involved both pharmacological and rehabilitative approaches.
A medical history of diagnosed with moderate elevated gamma-glutamyltransferase level was documented. Genetic analysis confirmed gene variant p.Arg953Cys. Supportive care and follow-up were recommended.
Initial symptoms included moderate eeg with parietal epileptiform discharges condition, episodic gait ataxia manifestation, clinical signs of chronic aphasia. Subsequent investigations showed gene variant c.3643+1G>A and c.2396C>A (p.S799Y). Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of presence of intermittent elevated gamma-glutamyltransferase level. Laboratory evaluations detected gene variant C752T (T251I) and C1760T (P587L). Clinical monitoring is ongoing.
A medical history of severe eeg with parietal epileptiform discharges detected, presence of mild abnormality of coagulation, persistent gait ataxia condition, presence of focal motor seizure was documented. Genetic analysis confirmed gene variant c.2584G>A p.A862T and c.830A>T p.H277L. Supportive care and follow-up were recommended.
Upon examination, presence of progressive gait ataxia, episodic abnormality of coagulation detected, diagnosed with severe eeg with parietal epileptiform discharges, episodic impaired vibratory sensation observed were noted. Further imaging and laboratory tests identified gene variant P765T. The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of eeg with parietal epileptiform discharges observed. Laboratory evaluations detected gene variant c.752C>T p.T251I and c.1760C>T p.P587L. Clinical monitoring is ongoing.
The individual was admitted with complaints of history of mild aphasia, severe focal motor seizure manifestation, presence of severe impaired vibratory sensation. Laboratory evaluations detected gene variant 1399G >A A467T and 2243G >C W748S. Clinical monitoring is ongoing.
Upon examination, persistent elevated gamma-glutamyltransferase level manifestation, presence of episodic stooped posture, sudden aphasia detected, history of acute eeg with parietal epileptiform discharges were noted. Further imaging and laboratory tests identified gene variant T251I/P587L and R807C. The patient was started on a tailored therapeutic plan.
A medical history of clinical signs of progressive eeg with parietal epileptiform discharges, intermittent reduced tendon reflexes symptoms, chronic aphasia symptoms was documented. Genetic analysis confirmed gene variant A467T and W748S. Supportive care and follow-up were recommended.
The patient presented to the clinic with presence of severe gait ataxia. Diagnostic workup revealed gene variant c.1535A>T p.K512M. Treatment was initiated accordingly.
Initial symptoms included acute eeg with parietal epileptiform discharges manifestation, diagnosed with chronic gait ataxia. Subsequent investigations showed gene variant p.Arg953Cys. Management involved both pharmacological and rehabilitative approaches.
A medical history of sudden impaired vibratory sensation manifestation, chronic aphasia symptoms was documented. Genetic analysis confirmed gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). Supportive care and follow-up were recommended.
Upon examination, severe focal motor seizure manifestation were noted. Further imaging and laboratory tests identified gene variant A467T. The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with episodic abnormality of coagulation observed, chronic eeg with parietal epileptiform discharges condition, diagnosed with chronic elevated gamma-glutamyltransferase level, acute action tremor manifestation. Diagnostic workup revealed gene variant 1399G→A (A467T). Treatment was initiated accordingly.
Initial symptoms included episodic aphasia detected, intermittent focal motor seizure detected. Subsequent investigations showed gene variant c.2993C>T p.998S>L and c.3550G>C p.1184D>H. Management involved both pharmacological and rehabilitative approaches.
Upon examination, presence of intermittent elevated gamma-glutamyltransferase level, clinical signs of reduced tendon reflexes, stooped posture detected were noted. Further imaging and laboratory tests identified gene variant c.752C>T (p.T251I) and c.3572A>G (p.K1191R). The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of sudden abnormality of coagulation condition, sudden action tremor symptoms. Laboratory evaluations detected gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). Clinical monitoring is ongoing.
The individual was admitted with complaints of presence of episodic eeg with parietal epileptiform discharges, presence of severe gait ataxia, acute elevated gamma-glutamyltransferase level observed, diagnosed with impaired vibratory sensation. Laboratory evaluations detected gene variant p.W748S and p.T914P. Clinical monitoring is ongoing.
A medical history of eeg with parietal epileptiform discharges condition was documented. Genetic analysis confirmed gene variant c.752C>T p.T251I and c.1760C>T p.P587L. Supportive care and follow-up were recommended.
Initial symptoms included severe action tremor, clinical signs of progressive reduced tendon reflexes, sudden elevated gamma-glutamyltransferase level manifestation, presence of episodic gait ataxia. Subsequent investigations showed gene variant 1399G>A A467T and 3573G>T K1191N. Management involved both pharmacological and rehabilitative approaches.
A medical history of progressive abnormality of coagulation, severe eeg with parietal epileptiform discharges detected, episodic stooped posture manifestation, diagnosed with sudden elevated gamma-glutamyltransferase level was documented. Genetic analysis confirmed gene variant c.1288A>T and c.2752T>C. Supportive care and follow-up were recommended.
Upon examination, intermittent eeg with parietal epileptiform discharges, moderate focal motor seizure detected, clinical signs of acute elevated gamma-glutamyltransferase level, presence of sudden stooped posture were noted. Further imaging and laboratory tests identified gene variant Tyr955Cys. The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of persistent eeg with parietal epileptiform discharges manifestation, history of sudden abnormality of coagulation, episodic action tremor symptoms. Laboratory evaluations detected gene variant c.1288A>T p.M430L and c.2752T>C p.W918R. Clinical monitoring is ongoing.
The individual was admitted with complaints of aphasia detected. Laboratory evaluations detected gene variant c.3102delG (p.Lys1035Serfs*59) and c.3286C>T (p.Arg1096Cys). Clinical monitoring is ongoing.
The individual was admitted with complaints of episodic gait ataxia detected, progressive aphasia detected, sudden eeg with parietal epileptiform discharges observed. Laboratory evaluations detected gene variant A467T and W748S. Clinical monitoring is ongoing.
A medical history of severe elevated gamma-glutamyltransferase level, diagnosed with gait ataxia was documented. Genetic analysis confirmed gene variant A467T. Supportive care and follow-up were recommended.
A medical history of reduced tendon reflexes, episodic impaired vibratory sensation manifestation, focal motor seizure manifestation, moderate elevated gamma-glutamyltransferase level observed was documented. Genetic analysis confirmed gene variant T251I/P587L and R807C. Supportive care and follow-up were recommended.
Initial symptoms included acute eeg with parietal epileptiform discharges symptoms, history of progressive elevated gamma-glutamyltransferase level, chronic stooped posture symptoms, sudden reduced tendon reflexes. Subsequent investigations showed gene variant c.3643+1G>A and c.2396C>A (p.S799Y). Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with sudden reduced tendon reflexes symptoms. Diagnostic workup revealed gene variant c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu). Treatment was initiated accordingly.
The patient presented to the clinic with episodic stooped posture symptoms, history of chronic aphasia. Diagnostic workup revealed gene variant R853W and G737R. Treatment was initiated accordingly.
Upon examination, intermittent reduced tendon reflexes condition, clinical signs of severe abnormality of coagulation, persistent focal motor seizure observed, episodic stooped posture condition were noted. Further imaging and laboratory tests identified gene variant c.1535A>T p.K512M. The patient was started on a tailored therapeutic plan.
Upon examination, clinical signs of sudden aphasia, acute reduced tendon reflexes detected, acute gait ataxia observed were noted. Further imaging and laboratory tests identified gene variant Tyr955Cys. The patient was started on a tailored therapeutic plan.
A medical history of acute eeg with parietal epileptiform discharges manifestation, persistent action tremor condition, intermittent gait ataxia observed, aphasia detected was documented. Genetic analysis confirmed gene variant p.W748S and p.T914P. Supportive care and follow-up were recommended.
The individual was admitted with complaints of chronic stooped posture manifestation, clinical signs of focal motor seizure, presence of action tremor. Laboratory evaluations detected gene variant c.3286C>T (p.Arg1096Cys). Clinical monitoring is ongoing.
Upon examination, progressive elevated gamma-glutamyltransferase level, intermittent abnormality of coagulation observed, diagnosed with aphasia, presence of progressive gait ataxia were noted. Further imaging and laboratory tests identified gene variant p.A467T and c.2157+5_6GC>AG. The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with clinical signs of chronic focal motor seizure. Diagnostic workup revealed gene variant c.1399G>A p.Ala467Thr and c.3626_3629dupGATA. Treatment was initiated accordingly.
Initial symptoms included intermittent aphasia. Subsequent investigations showed gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 − 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. Management involved both pharmacological and rehabilitative approaches.
Upon examination, clinical signs of persistent reduced tendon reflexes, presence of acute abnormality of coagulation were noted. Further imaging and laboratory tests identified gene variant c.2243G>C p.Trp748Ser. The patient was started on a tailored therapeutic plan.
The individual was admitted with complaints of presence of eeg with parietal epileptiform discharges, intermittent reduced tendon reflexes, episodic elevated gamma-glutamyltransferase level symptoms, diagnosed with abnormality of coagulation. Laboratory evaluations detected gene variant T251I/P587L and R807C. Clinical monitoring is ongoing.
A medical history of sudden action tremor observed, clinical signs of severe gait ataxia was documented. Genetic analysis confirmed gene variant c.3286C>T (p.Arg1096Cys). Supportive care and follow-up were recommended.
Initial symptoms included acute aphasia observed, clinical signs of elevated gamma-glutamyltransferase level, progressive abnormality of coagulation manifestation. Subsequent investigations showed gene variant A467T and W748S. Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included clinical signs of moderate impaired vibratory sensation. Subsequent investigations showed gene variant p.Arg1096His (c.3287G>A) and p.Arg953Cys (c.2857C>T). Management involved both pharmacological and rehabilitative approaches.
A medical history of clinical signs of stooped posture, sudden abnormality of coagulation was documented. Genetic analysis confirmed gene variant R853W and G737R. Supportive care and follow-up were recommended.
A medical history of clinical signs of progressive focal motor seizure was documented. Genetic analysis confirmed gene variant c.3286C>T (p.Arg1096Cys). Supportive care and follow-up were recommended.
The individual was admitted with complaints of clinical signs of moderate reduced tendon reflexes, presence of moderate eeg with parietal epileptiform discharges, history of episodic stooped posture. Laboratory evaluations detected gene variant A467T. Clinical monitoring is ongoing.
Upon examination, diagnosed with episodic action tremor were noted. Further imaging and laboratory tests identified gene variant c.2864A>G (p.Tyr955Cys). The patient was started on a tailored therapeutic plan.
Initial symptoms included history of episodic aphasia. Subsequent investigations showed gene variant W748S. Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included acute focal motor seizure symptoms, acute action tremor condition. Subsequent investigations showed gene variant P765T. Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with persistent elevated gamma-glutamyltransferase level observed, episodic abnormality of coagulation detected. Diagnostic workup revealed gene variant 1399G >A A467T and 2243G >C W748S. Treatment was initiated accordingly.
Initial symptoms included severe elevated gamma-glutamyltransferase level, history of severe stooped posture, moderate abnormality of coagulation manifestation. Subsequent investigations showed gene variant c.2243G>C p.Trp748Ser. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of moderate gait ataxia observed. Laboratory evaluations detected gene variant c.3102delG (p.Lys1035Serfs*59) and c.3286C>T (p.Arg1096Cys). Clinical monitoring is ongoing.
A medical history of presence of episodic gait ataxia was documented. Genetic analysis confirmed . Supportive care and follow-up were recommended.
The individual was admitted with complaints of progressive action tremor observed, sudden stooped posture symptoms, severe impaired vibratory sensation. Laboratory evaluations detected gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. Clinical monitoring is ongoing.
A medical history of diagnosed with intermittent elevated gamma-glutamyltransferase level was documented. Genetic analysis confirmed gene variant W748S and c.3643+2T>C. Supportive care and follow-up were recommended.
A medical history of chronic action tremor manifestation, sudden eeg with parietal epileptiform discharges symptoms, mild aphasia observed, diagnosed with gait ataxia was documented. Genetic analysis confirmed gene variant c.2584G>A p.A862T and c.830A>T p.H277L. Supportive care and follow-up were recommended.
Initial symptoms included chronic abnormality of coagulation symptoms, chronic action tremor manifestation, moderate elevated gamma-glutamyltransferase level symptoms. Subsequent investigations showed gene variant c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu). Management involved both pharmacological and rehabilitative approaches.
A medical history of history of acute eeg with parietal epileptiform discharges was documented. Genetic analysis confirmed gene variant 1399G→A (A467T). Supportive care and follow-up were recommended.
Initial symptoms included moderate gait ataxia symptoms, history of acute stooped posture, eeg with parietal epileptiform discharges manifestation. Subsequent investigations showed gene variant 1399G>A A467T and 3573G>T K1191N. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of clinical signs of episodic eeg with parietal epileptiform discharges. Laboratory evaluations detected gene variant p.A467T and c.2157+5_6GC>AG. Clinical monitoring is ongoing.
A medical history of progressive aphasia, clinical signs of moderate action tremor, diagnosed with moderate eeg with parietal epileptiform discharges, history of intermittent impaired vibratory sensation was documented. Genetic analysis confirmed . Supportive care and follow-up were recommended.
The individual was admitted with complaints of episodic gait ataxia symptoms, moderate aphasia detected. Laboratory evaluations detected gene variant 1399G>A A467T and 3573G>T K1191N. Clinical monitoring is ongoing.
The individual was admitted with complaints of clinical signs of reduced tendon reflexes, clinical signs of persistent aphasia, chronic abnormality of coagulation symptoms. Laboratory evaluations detected gene variant p.Arg1096His (c.3287G>A) and p.Arg953Cys (c.2857C>T). Clinical monitoring is ongoing.
A medical history of episodic gait ataxia symptoms, history of sudden aphasia, sudden elevated gamma-glutamyltransferase level condition was documented. Genetic analysis confirmed gene variant c.752C>T p.T251I and c.1760C>T p.P587L. Supportive care and follow-up were recommended.
The individual was admitted with complaints of episodic eeg with parietal epileptiform discharges, intermittent aphasia, presence of mild focal motor seizure, intermittent gait ataxia symptoms. Laboratory evaluations detected gene variant p.Arg953Cys. Clinical monitoring is ongoing.
A medical history of presence of mild reduced tendon reflexes, mild abnormality of coagulation observed was documented. Genetic analysis confirmed gene variant c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu). Supportive care and follow-up were recommended.
The patient presented to the clinic with severe abnormality of coagulation, diagnosed with chronic focal motor seizure, progressive stooped posture symptoms. Diagnostic workup revealed gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 − 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. Treatment was initiated accordingly.
The patient presented to the clinic with mild aphasia. Diagnostic workup revealed gene variant c.1399G>A p.Ala467Thr and c.3626_3629dupGATA. Treatment was initiated accordingly.
The patient presented to the clinic with stooped posture symptoms. Diagnostic workup revealed gene variant c.679C>T p.R227W and c.2542G>A p.G848S. Treatment was initiated accordingly.
Initial symptoms included clinical signs of persistent stooped posture, history of moderate aphasia, presence of acute abnormality of coagulation, presence of intermittent eeg with parietal epileptiform discharges. Subsequent investigations showed gene variant c911T > G (p. L304R) and 3240-3242 duplication (pR1081dup). Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of elevated gamma-glutamyltransferase level detected. Laboratory evaluations detected gene variant c911T > G (p. L304R) and 3240-3242 duplication (pR1081dup). Clinical monitoring is ongoing.
Initial symptoms included clinical signs of intermittent aphasia, chronic elevated gamma-glutamyltransferase level detected. Subsequent investigations showed gene variant A467T. Management involved both pharmacological and rehabilitative approaches.
A medical history of presence of progressive abnormality of coagulation, diagnosed with progressive stooped posture was documented. Genetic analysis confirmed gene variant c.752C>T p.T251I and c.1760C>T p.P587L. Supportive care and follow-up were recommended.
A medical history of clinical signs of intermittent impaired vibratory sensation was documented. Genetic analysis confirmed gene variant c.3311C>G (p.S1104C) and c.2542G>A (p.G848S). Supportive care and follow-up were recommended.
A medical history of progressive stooped posture condition, intermittent aphasia symptoms was documented. Genetic analysis confirmed gene variant c.752C>T (p.T251I) and c.2542G>A (p.G848S). Supportive care and follow-up were recommended.
Upon examination, progressive reduced tendon reflexes observed, progressive abnormality of coagulation symptoms, sudden aphasia symptoms were noted. Further imaging and laboratory tests identified gene variant c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu). The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with sudden abnormality of coagulation. Diagnostic workup revealed gene variant c.1399G>A p.Ala467Thr and c.2542G>A p.Gly848Ser. Treatment was initiated accordingly.
Upon examination, severe focal motor seizure symptoms, episodic reduced tendon reflexes symptoms, moderate aphasia condition were noted. Further imaging and laboratory tests identified gene variant W748S. The patient was started on a tailored therapeutic plan.
Upon examination, acute abnormality of coagulation observed, history of progressive aphasia, history of episodic action tremor were noted. Further imaging and laboratory tests identified gene variant Tyr955Cys. The patient was started on a tailored therapeutic plan.
Upon examination, acute stooped posture detected, acute eeg with parietal epileptiform discharges detected were noted. Further imaging and laboratory tests identified gene variant c.752C>T p.T251I and c.1760C>T p.P587L. The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with aphasia symptoms, persistent action tremor condition, history of moderate eeg with parietal epileptiform discharges, episodic abnormality of coagulation observed. Diagnostic workup revealed gene variant c.2584G>A p.A862T and c.830A>T p.H277L. Treatment was initiated accordingly.
A medical history of episodic abnormality of coagulation condition, diagnosed with chronic reduced tendon reflexes was documented. Genetic analysis confirmed gene variant c3239G>C p.Ser1080Thr. Supportive care and follow-up were recommended.
A medical history of history of mild abnormality of coagulation, clinical signs of severe focal motor seizure, history of sudden aphasia was documented. Genetic analysis confirmed gene variant c.2864A>G (p.Tyr955Cys). Supportive care and follow-up were recommended.
Upon examination, clinical signs of persistent abnormality of coagulation were noted. Further imaging and laboratory tests identified gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). The patient was started on a tailored therapeutic plan.
A medical history of clinical signs of intermittent elevated gamma-glutamyltransferase level, clinical signs of aphasia was documented. Genetic analysis confirmed gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). Supportive care and follow-up were recommended.
The individual was admitted with complaints of severe impaired vibratory sensation symptoms, mild gait ataxia detected, diagnosed with acute reduced tendon reflexes. Laboratory evaluations detected gene variant c.3643+1G>A and c.2396C>A (p.S799Y). Clinical monitoring is ongoing.
Initial symptoms included impaired vibratory sensation condition. Subsequent investigations showed gene variant c.1399G>A p.Ala467Thr and c.3626_3629dupGATA. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of acute abnormality of coagulation symptoms, history of mild aphasia. Laboratory evaluations detected gene variant A467T. Clinical monitoring is ongoing.
A medical history of acute eeg with parietal epileptiform discharges, moderate elevated gamma-glutamyltransferase level detected, severe impaired vibratory sensation detected, presence of sudden gait ataxia was documented. Genetic analysis confirmed gene variant c.752C>T (p.T251I) and c.2542G>A (p.G848S). Supportive care and follow-up were recommended.
The patient presented to the clinic with diagnosed with reduced tendon reflexes, moderate abnormality of coagulation observed, severe focal motor seizure manifestation, clinical signs of sudden gait ataxia. Diagnostic workup revealed gene variant R853W and G737R. Treatment was initiated accordingly.
A medical history of episodic eeg with parietal epileptiform discharges, persistent reduced tendon reflexes detected, presence of sudden elevated gamma-glutamyltransferase level, severe abnormality of coagulation manifestation was documented. Genetic analysis confirmed gene variant p.Arg953Cys. Supportive care and follow-up were recommended.
The individual was admitted with complaints of diagnosed with episodic aphasia, mild reduced tendon reflexes observed, acute focal motor seizure observed, moderate elevated gamma-glutamyltransferase level symptoms. Laboratory evaluations detected gene variant c.752C>T (p.T251I) and c.2542G>A (p.G848S). Clinical monitoring is ongoing.
A medical history of clinical signs of chronic elevated gamma-glutamyltransferase level, history of progressive reduced tendon reflexes, moderate action tremor detected, presence of progressive stooped posture was documented. Genetic analysis confirmed gene variant A467T and W748S. Supportive care and follow-up were recommended.
The patient presented to the clinic with episodic abnormality of coagulation manifestation. Diagnostic workup revealed gene variant c. 2243G>C (p. W748S). Treatment was initiated accordingly.
Upon examination, chronic abnormality of coagulation manifestation, history of severe impaired vibratory sensation, moderate action tremor, clinical signs of intermittent focal motor seizure were noted. Further imaging and laboratory tests identified gene variant c.3102delG (p.Lys1035Serfs*59) and c.3286C>T (p.Arg1096Cys). The patient was started on a tailored therapeutic plan.
The patient presented to the clinic with moderate elevated gamma-glutamyltransferase level symptoms, mild impaired vibratory sensation manifestation, persistent action tremor. Diagnostic workup revealed gene variant T251I/P587L and R807C. Treatment was initiated accordingly.
The individual was admitted with complaints of sudden action tremor manifestation, clinical signs of chronic abnormality of coagulation. Laboratory evaluations detected gene variant c.3102delG (p.Lys1035Serfs*59) and c.3286C>T (p.Arg1096Cys). Clinical monitoring is ongoing.
Upon examination, diagnosed with aphasia, chronic stooped posture observed were noted. Further imaging and laboratory tests identified gene variant c.2243G>C. The patient was started on a tailored therapeutic plan.
Initial symptoms included clinical signs of intermittent gait ataxia. Subsequent investigations showed gene variant p.W748S and p.T914P. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of clinical signs of chronic abnormality of coagulation, sudden stooped posture, diagnosed with action tremor. Laboratory evaluations detected gene variant P765T. Clinical monitoring is ongoing.
A medical history of presence of severe abnormality of coagulation, sudden focal motor seizure detected, sudden reduced tendon reflexes, severe stooped posture symptoms was documented. Genetic analysis confirmed gene variant c.752C>T (p.T251I) and c.3572A>G (p.K1191R). Supportive care and follow-up were recommended.
A medical history of mild eeg with parietal epileptiform discharges detected, presence of intermittent impaired vibratory sensation, intermittent abnormality of coagulation symptoms was documented. Genetic analysis confirmed gene variant W748S. Supportive care and follow-up were recommended.
Initial symptoms included acute elevated gamma-glutamyltransferase level manifestation, intermittent aphasia condition, presence of episodic stooped posture. Subsequent investigations showed gene variant c3239G>C p.Ser1080Thr. Management involved both pharmacological and rehabilitative approaches.
The individual was admitted with complaints of clinical signs of mild impaired vibratory sensation, mild abnormality of coagulation manifestation. Laboratory evaluations detected gene variant c.1288A>T p.M430L and c.2752T>C p.W918R. Clinical monitoring is ongoing.
Initial symptoms included moderate action tremor, progressive elevated gamma-glutamyltransferase level symptoms, moderate abnormality of coagulation. Subsequent investigations showed gene variant c.3311C>G (p.S1104C) and c.2542G>A (p.G848S). Management involved both pharmacological and rehabilitative approaches.
Initial symptoms included severe stooped posture observed, history of elevated gamma-glutamyltransferase level. Subsequent investigations showed gene variant W748S. Management involved both pharmacological and rehabilitative approaches.
The patient presented to the clinic with intermittent action tremor manifestation. Diagnostic workup revealed gene variant p.Arg627Gln and p.Arg852Cys. Treatment was initiated accordingly.
A medical history of episodic gait ataxia detected, diagnosed with episodic aphasia, progressive abnormality of coagulation symptoms was documented. Genetic analysis confirmed gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 − 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. Supportive care and follow-up were recommended.
A medical history of diagnosed with elevated gamma-glutamyltransferase level, severe focal motor seizure condition, mild gait ataxia manifestation, clinical signs of sudden stooped posture was documented. Genetic analysis confirmed gene variant c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu). Supportive care and follow-up were recommended.
The individual was admitted with complaints of clinical signs of persistent impaired vibratory sensation. Laboratory evaluations detected gene variant c3239G>C p.Ser1080Thr. Clinical monitoring is ongoing.
The patient presented to the clinic with severe abnormality of coagulation symptoms, persistent eeg with parietal epileptiform discharges manifestation. Diagnostic workup revealed gene variant c.3286C>T (p.Arg1096Cys). Treatment was initiated accordingly.
The patient presented to the clinic with clinical signs of sudden reduced tendon reflexes, persistent eeg with parietal epileptiform discharges observed, acute gait ataxia symptoms, presence of chronic focal motor seizure. Diagnostic workup revealed gene variant 1399G>A A467T and 3573G>T K1191N. Treatment was initiated accordingly.
Upon examination, episodic eeg with parietal epileptiform discharges observed, intermittent action tremor manifestation, diagnosed with sudden impaired vibratory sensation, moderate reduced tendon reflexes observed were noted. Further imaging and laboratory tests identified gene variant W748S. The patient was started on a tailored therapeutic plan.
